Compare Stocks: RNXT, ELMD, PROF, and PDEX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELMD Electromed	$27.69 -0.4%	$32.42	$23.01 ▼ $47.40	$230.38M	0.4	78,847 shs	51,017 shs
PDEX Pro-Dex	$62.49 +0.5%	$66.65	$23.47 ▼ $77.00	$202.04M	0.04	66,526 shs	31,864 shs
PROF Profound Medical	$6.90 -0.1%	$6.57	$4.80 ▼ $8.95	$252.64M	0.75	291,630 shs	420,098 shs
RNXT RenovoRx	$1.28 -3.8%	$1.56	$0.70 ▼ $2.59	$60.02M	0.98	618,175 shs	797,991 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELMD Electromed	-0.40%	-1.46%	+2.29%	-39.34%	+10.23%
PDEX Pro-Dex	+0.45%	-2.47%	+2.95%	-0.64%	+79.88%
PROF Profound Medical	-0.14%	+18.15%	+1.47%	-1.99%	+2.37%
RNXT RenovoRx	-3.76%	-18.99%	-36.00%	+37.62%	+5.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELMD Electromed	$27.69 -0.4%	$32.42	$23.01 ▼ $47.40	$230.38M	0.4	78,847 shs	51,017 shs
PDEX Pro-Dex	$62.49 +0.5%	$66.65	$23.47 ▼ $77.00	$202.04M	0.04	66,526 shs	31,864 shs
PROF Profound Medical	$6.90 -0.1%	$6.57	$4.80 ▼ $8.95	$252.64M	0.75	291,630 shs	420,098 shs
RNXT RenovoRx	$1.28 -3.8%	$1.56	$0.70 ▼ $2.59	$60.02M	0.98	618,175 shs	797,991 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELMD Electromed	-0.40%	-1.46%	+2.29%	-39.34%	+10.23%
PDEX Pro-Dex	+0.45%	-2.47%	+2.95%	-0.64%	+79.88%
PROF Profound Medical	-0.14%	+18.15%	+1.47%	-1.99%	+2.37%
RNXT RenovoRx	-3.76%	-18.99%	-36.00%	+37.62%	+5.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELMD Electromed	2.75	Moderate Buy	$43.75	58.00% Upside
PDEX Pro-Dex	3.33	Buy	$74.00	18.42% Upside
PROF Profound Medical	2.67	Moderate Buy	$11.50	66.67% Upside
RNXT RenovoRx	2.75	Moderate Buy	$8.50	564.06% Upside

Current Analyst Ratings Breakdown

Latest RNXT, ELMD, PROF, and PDEX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	PDEX Pro-Dex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B)
10/8/2026	PROF Profound Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/21/2026	PDEX Pro-Dex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
9/15/2026	PDEX Pro-Dex	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/11/2026	PDEX Pro-Dex	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$70.00 ➝ $74.00
9/4/2026	PDEX Pro-Dex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
9/2/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	ELMD Electromed	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$50.00
8/26/2026	ELMD Electromed	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$36.00 ➝ $47.00
8/24/2026	PDEX Pro-Dex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/18/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELMD Electromed	$73.78M	3.11	$0.67 per share	41.36	$5.10 per share	5.43
PDEX Pro-Dex	$77.55M	2.61	$3.92 per share	15.94	$14.92 per share	4.19
PROF Profound Medical	$16.10M	15.67	N/A	N/A	$1.83 per share	3.77
RNXT RenovoRx	$1.98M	29.23	N/A	N/A	$0.15 per share	8.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELMD Electromed	$5.15M	$1.31	36.92	N/A	N/A	11.34%	15.71%	13.37%	N/A
PDEX Pro-Dex	$13.66M	$4.13	15.13	18.60	N/A	17.62%	25.13%	16.02%	10/29/2026 (Estimated)
PROF Profound Medical	-$42.57M	-$0.98	N/A	N/A	N/A	-171.57%	-63.03%	-51.24%	11/5/2026 (Estimated)
RNXT RenovoRx	-$11.17M	-$0.31	N/A	N/A	N/A	-621.71%	-135.11%	-101.91%	11/12/2026 (Estimated)

Latest RNXT, ELMD, PROF, and PDEX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	PROF Profound Medical	-$0.23	N/A	N/A	N/A	$8.82 million	N/A
10/29/2026	Q1 2027	PDEX Pro-Dex	$0.67	N/A	N/A	N/A	$20.40 million	N/A
9/3/2026	Q4 2026	PDEX Pro-Dex	$0.67	$0.87	+$0.20	$0.87	$19.20 million	$20.41 million
8/12/2026	Q2 2026	RNXT RenovoRx	-$0.0725	-$0.05	+$0.0225	-$0.06	$0.70 million	$0.91 million
8/6/2026	Q2 2026	PROF Profound Medical	-$0.22	-$0.26	-$0.04	$0.26	$4.75 million	$2.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELMD Electromed	N/A	N/A	N/A	N/A	N/A
PDEX Pro-Dex	N/A	N/A	N/A	N/A	N/A
PROF Profound Medical	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELMD Electromed	N/A	5.10	4.74
PDEX Pro-Dex	0.28	4.10	2.45
PROF Profound Medical	N/A	6.46	5.31
RNXT RenovoRx	N/A	5.74	5.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELMD Electromed	40.82%
PDEX Pro-Dex	15.28%
PROF Profound Medical	47.86%
RNXT RenovoRx	3.10%

Insider Ownership

Company	Insider Ownership
ELMD Electromed	11.00%
PDEX Pro-Dex	45.90%
PROF Profound Medical	1.52%
RNXT RenovoRx	9.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELMD Electromed	197	8.29 million	7.36 million	Optionable
PDEX Pro-Dex	206	3.23 million	1.75 million	Not Optionable
PROF Profound Medical	162	36.56 million	36.01 million	Optionable
RNXT RenovoRx	17	45.13 million	40.89 million	Not Optionable

RNXT, ELMD, PROF, and PDEX Headlines

Recent News About These Companies

RenovoRx Advances TAMP into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

October 8 at 7:29 PM | marketscreener.comM

RenovoRx Enrolls First Patient In UVM-Sponsored Pancreatic Cancer PRISM-TAMP Trial

October 8 at 9:28 AM | rttnews.com

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

October 7 at 8:30 AM | globenewswire.com

Medline (NASDAQ:MDLN) versus RenovoRx (NASDAQ:RNXT) Head-To-Head Comparison

October 5, 2026 | americanbankingnews.com

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

October 1, 2026 | globenewswire.com

RenovoRx, Inc. (NASDAQ:RNXT) Stock Short Interest Jumps 55.7%

October 1, 2026 | marketbeat.com

RenovoRx, Inc. (NASDAQ:RNXT) Short Interest Update

September 17, 2026 | marketbeat.com

RenovoRx HC Wainwright presentation to highlight RenovoCath growth and Phase III TIGeR-PaC timeline

September 2, 2026 | msn.com

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

September 2, 2026 | globenewswire.com

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced ...

August 25, 2026 | finance.yahoo.com

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

August 25, 2026 | globenewswire.com

RenovoRx (NASDAQ:RNXT) Gains Attention After Compliance Update

August 21, 2026 | kalkinemedia.comK

RenovoRx regains Nasdaq compliance

August 21, 2026 | msn.com

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

August 21, 2026 | globenewswire.com

RenovoRx Regains Nasdaq Compliance on Minimum Bid Price

August 20, 2026 | tipranks.com

RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

August 20, 2026 | globenewswire.com

RenovoRx (RNXT) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

RenovoRx, Inc. (RNXT) Q2 FY2026 earnings call transcript

August 12, 2026 | finance.yahoo.com

RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates

August 12, 2026 | zacks.com

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

August 12, 2026 | markets.businessinsider.com

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

August 11, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RNXT, ELMD, PROF, and PDEX Company Descriptions

Electromed NYSE:ELMD

$27.69 -0.11 (-0.40%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$27.41 -0.28 (-1.03%)

As of 10/9/2026 08:00 PM Eastern

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.

Pro-Dex NASDAQ:PDEX

$62.49 +0.28 (+0.45%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$62.50 +0.01 (+0.02%)

As of 10/9/2026 07:32 PM Eastern

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Profound Medical NASDAQ:PROF

$6.90 -0.01 (-0.14%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$6.92 +0.01 (+0.22%)

As of 10/9/2026 07:42 PM Eastern

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

RenovoRx NASDAQ:RNXT

$1.28 -0.05 (-3.76%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.30 +0.02 (+1.64%)

As of 10/9/2026 07:56 PM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNXT, ELMD, PROF, and PDEX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNXT, ELMD, PROF, and PDEX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNXT, ELMD, PROF, and PDEX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RNXT, ELMD, PROF, and PDEX Company Descriptions

Electromed NYSE:ELMD

Pro-Dex NASDAQ:PDEX

Profound Medical NASDAQ:PROF

RenovoRx NASDAQ:RNXT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNXT, ELMD, PROF, and PDEX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNXT, ELMD, PROF, and PDEX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNXT, ELMD, PROF, and PDEX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RNXT, ELMD, PROF, and PDEX Company Descriptions

Electromed NYSE:ELMD

Pro-Dex NASDAQ:PDEX

Profound Medical NASDAQ:PROF

RenovoRx NASDAQ:RNXT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools